IgA nephropathy: a review of existing and emerging therapies
IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Nephrology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneph.2023.1175088/full |
| _version_ | 1797821825449721856 |
|---|---|
| author | Sahibzadi Mahrukh Noor Farah Abuazzam Roy Mathew Zhiwei Zhang Amir Abdipour Sayna Norouzi |
| author_facet | Sahibzadi Mahrukh Noor Farah Abuazzam Roy Mathew Zhiwei Zhang Amir Abdipour Sayna Norouzi |
| author_sort | Sahibzadi Mahrukh Noor |
| collection | DOAJ |
| description | IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials. |
| first_indexed | 2024-03-13T09:58:32Z |
| format | Article |
| id | doaj.art-4f1ebca36b7c4427a94207721c3d91d2 |
| institution | Directory Open Access Journal |
| issn | 2813-0626 |
| language | English |
| last_indexed | 2024-03-13T09:58:32Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nephrology |
| spelling | doaj.art-4f1ebca36b7c4427a94207721c3d91d22023-05-23T08:31:33ZengFrontiers Media S.A.Frontiers in Nephrology2813-06262023-05-01310.3389/fneph.2023.11750881175088IgA nephropathy: a review of existing and emerging therapiesSahibzadi Mahrukh NoorFarah AbuazzamRoy MathewZhiwei ZhangAmir AbdipourSayna NorouziIgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.https://www.frontiersin.org/articles/10.3389/fneph.2023.1175088/fullIgA nephropathyproteinuriaSGLT2 inhibitorsglucocorticoidsbudesonidesparsentan |
| spellingShingle | Sahibzadi Mahrukh Noor Farah Abuazzam Roy Mathew Zhiwei Zhang Amir Abdipour Sayna Norouzi IgA nephropathy: a review of existing and emerging therapies Frontiers in Nephrology IgA nephropathy proteinuria SGLT2 inhibitors glucocorticoids budesonide sparsentan |
| title | IgA nephropathy: a review of existing and emerging therapies |
| title_full | IgA nephropathy: a review of existing and emerging therapies |
| title_fullStr | IgA nephropathy: a review of existing and emerging therapies |
| title_full_unstemmed | IgA nephropathy: a review of existing and emerging therapies |
| title_short | IgA nephropathy: a review of existing and emerging therapies |
| title_sort | iga nephropathy a review of existing and emerging therapies |
| topic | IgA nephropathy proteinuria SGLT2 inhibitors glucocorticoids budesonide sparsentan |
| url | https://www.frontiersin.org/articles/10.3389/fneph.2023.1175088/full |
| work_keys_str_mv | AT sahibzadimahrukhnoor iganephropathyareviewofexistingandemergingtherapies AT farahabuazzam iganephropathyareviewofexistingandemergingtherapies AT roymathew iganephropathyareviewofexistingandemergingtherapies AT zhiweizhang iganephropathyareviewofexistingandemergingtherapies AT amirabdipour iganephropathyareviewofexistingandemergingtherapies AT saynanorouzi iganephropathyareviewofexistingandemergingtherapies |